Systemic NF-κB activation in blood cells of breast cancer patients

被引:12
|
作者
Adzic, M
Niciforovic, A
Vucic, V
Neskovic-Konstantinovic, Z
Spasic, SD
Jones, DR
Radojcic, MB
Spasic, MB
机构
[1] Sinisa Stankovic, Dept Physiol, Inst Biol Res, Belgrade 11000, Serbia Monteneg
[2] Sinisa Stankovic, VINCA Inst Nucl Sci, Belgrade, Serbia Monteneg
[3] Sinisa Stankovic, Inst Oncol & Radiol Serbia, Belgrade, Serbia Monteneg
[4] Sinisa Stankovic, Ctr Chem ICHTM, Belgrade, Serbia Monteneg
[5] Sinisa Stankovic, Fac Chem, Dept Biochem, Belgrade, Serbia Monteneg
关键词
NF-kappa B; Mn-SOD; CAT; breast cancer;
D O I
10.1179/135100006X101002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There is a well-established role for reactive oxygen and nitrogen species, chronic inflammation and immune response in the pathogenesis of breast cancer. Complex interactions between breast cancer cells and surrounding blood vessels are prerequisites for cancer growth and invasion. Reports in the literature concerning the systemic response to, and the effect of, common breast cancer therapy on NF-kappa B and antioxidative defence enzyme expression and activity under clinical conditions are scarce. We determined these parameters in whole blood cell lysate from 16 women with breast cancer before and after combined (cyclophosphamide, doxorubicin, 5-fluorouracil; CAF) therapy and compared the results with 16 healthy women. Significantly higher levels of NF-kappa B and Mn-SOD (both their protein level and their activity) were found in breast cancer patients before and after CAF therapy, in comparison with healthy women. In parallel measurements, no change in the level or activity of catalase (CAT) was detected. According to our findings, it appears that breast cancer creates conditions that increase the level of hydrogen peroxide in the circulating cells and that the applied CAF therapy fails to compensate, therefore creating systemic conditions that favour survival and invasion of breast cancer cells.
引用
收藏
页码:38 / 44
页数:6
相关论文
共 50 条
  • [1] Activation of NFκB in breast cancer cells
    Nehra, Ruchi
    Riggins, Rebecca B.
    Zwart, Alan L.
    Clarke, Robert
    CANCER RESEARCH, 2006, 66 (08)
  • [2] NF-κB and breast cancer
    Johnstone, PAS
    Takimoto, CHM
    Goulet, R
    CURRENT PROBLEMS IN CANCER, 2002, 26 (05) : 282 - 309
  • [3] Overexpression of NF-κB inducing kinase underlies constitutive NF-κB activation in lung cancer cells
    Saitoh, Yasunori
    Bruyn, Vicente Javier Martinez
    Uota, Shin
    Hasegawa, Atsuhiko
    Yamamoto, Naoki
    Imoto, Issei
    Inazawa, Johji
    Yamaoka, Shoji
    LUNG CANCER, 2010, 70 (03) : 263 - 270
  • [4] Identification of signal transduction pathways involved in constitutive NF-κB activation in breast cancer cells
    Poornima Bhat-Nakshatri
    Christopher J Sweeney
    Harikrishna Nakshatri
    Oncogene, 2002, 21 : 2066 - 2078
  • [5] Identification of signal transduction pathways involved in constitutive NF-κB activation in breast cancer cells
    Bhat-Nakshatri, P
    Sweeney, CJ
    Nakshatri, H
    ONCOGENE, 2002, 21 (13) : 2066 - 2078
  • [6] Genistein inhibits NF-κB activation in prostate cancer cells
    Davis, JN
    Kucuk, O
    Sarkar, FH
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 1999, 35 (02): : 167 - 174
  • [7] SENP2 suppresses NF-κB activation and sensitizes breast cancer cells to doxorubicin
    Gao, Xiaoyu
    Wu, Yudan
    Qiao, Lele
    Feng, Xiaoshan
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 854 : 179 - 186
  • [8] NF-κB-mediated chemoresistance in breast cancer cells
    Weldon, CB
    Burow, ME
    Rolfe, KW
    Clayton, JL
    Jaffe, BM
    Beckman, BS
    SURGERY, 2001, 130 (02) : 143 - 150
  • [9] NF-κB activation in peripheral blood mononuclear cells in neonatal asphyxia
    Hasegawa, K
    Ichiyama, T
    Isumi, H
    Nakata, M
    Sase, M
    Furukawa, S
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2003, 132 (02): : 261 - 264
  • [10] Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells
    Ma, Chuandong
    Zuo, Wenshu
    Wang, Xingwu
    Wei, Ling
    Guo, Qian
    Song, Xianrang
    ONCOLOGY REPORTS, 2013, 29 (02) : 812 - 818